PubMed Health⌕ Search

PubMed · 16599875

Oxygenation is not improved by partial liquid high frequency ventilation using a high lung volume strategy. An experimental study.

Abstract

OBJECTIVE: To investigate the effect on oxygenation and lung damage of partial perfluorocarbon liquid high frequency oscillatory ventilation (PL-HFOV) versus high frequency oscillatory ventilation (HFOV) alone, in rabbits with acute lung injury, using high lung volume strategy HFOV. METHODS: Twelve adult New Zealand white rabbits were initially ventilated with HFOV after anaesthesia, sedation and paralysis. After induction of lung injury with saline lavage, all animals received a single sigh breath of 30 cmH(2)O for 30 seconds. They were then allocated to receive either HFOV alone (n = 6) or PL-HFOV (n = 6). Arterial blood gases were taken pre- and post-lavage and then hourly for 5 hours. The oxygenation index (OI, in cmH(2)O/mmHg) was calculated using the formula: OI = (MAP x F(I)O(2) x 100) / PaO(2). The lungs were then removed for histological examination to score lung injury. RESULTS: Two rabbits died in the PL-HFOV group and none in the HFOV group, p = 0.45 (Fisher's exact test). At one hour the oxygenation index (OI) was 4.5 in the HFOV group and 6.6 in the PL-HFOV group, p = 0.49 and the PaO(2) was 374 mmHg in the HFOV group and 311 mmHg in the PL-HFOV group, p = 0.39. Average OI over the first three hours was 3.6 in the HFOV group and 5.0 in the PL-HFOV group, p = 0.27 and the PaO(2) was 404 mmHg in the HFOV group and 337 mmHg in the PL-HFOV group, p = 0.12. The lung histology damage score was 2.33 in the HFOV group and 2.50 in the PL-HFOV group, p = 0.83. CONCLUSIONS: In this model of acute lung injury, using a high volume HFOV strategy to optimise lung recruitment, PL-HFOV did not result in any further improvement in oxygenation when compared with HFOV alone. The question of safety with PL-HFOV remains.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M W Davies, M J Stewart, M Souriel, R Chavasse, W Butt. 1999. Oxygenation is not improved by partial liquid high frequency ventilation using a high lung volume strategy. An experimental study.. https://pubmed.ncbi.nlm.nih.gov/16599875/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗